Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114791 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PRKCACYP1A2NOS3NOS1 | |
| SCHEMBL9172090 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PRKCACYP1A2NOS3NOS1 | |
| SCHEMBL9171420 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PRKCACYP1A2NOS3NOS1 | |
| SCHEMBL7178100 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PRKCACYP1A2NOS3NOS1 | |
| SCHEMBL14994441 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PRKCACYP1A2NOS3NOS1 | |
| SCHEMBL7180354 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PRKCACYP1A2NOS3NOS1 | |
| SCHEMBL9171097 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PRKCACYP1A2NOS3NOS1 | |
| SCHEMBL30754370 | 0.94 | CYP1A2 (0.47) | SMN1; SMN2PRKCACYP1A2PPARG | |
| SCHEMBL2146282 | 0.94 | CYP1A2 (0.47) | SMN1; SMN2PRKCACYP1A2PPARG | |
| SCHEMBL2512382 | 0.92 | CYP1A2 (0.50) | PRKCACYP1A2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037539-B2 | Alkyl lactone-derived hydroxyamides and alkyl lactone-derived hydroxyesters for the control of natural gas hydrates | CHAMPIONX LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-6579992-B2 | Use for flavouring a wide range of food stuffs including baked goods, beverages, and confectionery | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-06-17 | — | — | US | disclosed |
| US-20020137949-A1 | Novel method for converting dihydrotagetone, a bifuctional acyclic monoterpene ketone, isolated from the plant species of tagetes, into a coconut flavoured two chiral centered compound 5-isobutyl-3-methyl-4,5-dihydro-2(3H)-furanone as a novel analogue of natural whisky lactone and coconut aldehyde | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137949-A1 | Novel method for converting dihydrotagetone, a bifuctional acyclic monoterpene ketone, isolated from the plant species of tagetes, into a coconut flavoured two chiral centered compound 5-isobutyl-3-methyl-4,5-dihydro-2(3H)-furanone as a novel analogue of natural whisky lactone and coconut aldehyde | ADH1C, ADH5, ME1 | SMN1; SMN2 2076/4885PRKCA 1612/4885CYP1A2 934/4885 |
| US-12037539-B2 | Alkyl lactone-derived hydroxyamides and alkyl lactone-derived hydroxyesters for the control of natural gas hydrates | HDHD5, HACL2, ADH5 | SMN1; SMN2 4868/4885PRKCA 4271/4885CYP1A2 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.